Please login to the form below

Not currently logged in
Email:
Password:

Flutiform

This page shows the latest Flutiform news and features for those working in and with pharma, biotech and healthcare.

Vectura's Flutiform flunks phase III COPD test

Vectura's Flutiform flunks phase III COPD test

Vectura's Flutiform flunks phase III COPD test. But new AirFluSal data demonstrates superior patient adherence over GSK’ s Seretide/Advair. ... Flutiform sales doubled last year to reach 144m in 2015, and in the first six months of this year grew

Latest news

  • Vectura to merge with SkyePharma in £441m deal Vectura to merge with SkyePharma in £441m deal

    SkyePharma has just reported record revenues for 2015 of £95m, up 30% with the help of rising royalties and product supply fees for asthma therapy Flutiform (fluticasone/formoterol) and GlaxoSmithKline's

  • Successful partnerships in pharma: Skyepharma and Mundipharma Successful partnerships in pharma: Skyepharma and Mundipharma

    was able to make decisions quickly and was equally committed to the success of Flutiform. ... Mundipharma International was attracted to Flutiform because it offered patients a novel combination of an established bronchodilator and antiinflammatory.

  • Double asthma approval in Japan lifts SkyePharma Double asthma approval in Japan lifts SkyePharma

    The Japanese Ministry of Health, Labour and Welfare (MHLW) cleared GlaxoSmithKline's (GSK) Relvar Ellipta (vilanterol and fluticasone), as well as Kyorin Pharmaceutical's Flutiform (formoterol and fluticasone) for the treatment ... Meanwhile, the

  • Portland Health wins Mundipharma account

    High on the Portland Health's agenda will be to raise the profile of the recently launched asthma drug Flutiform (fluticasone/formoterol).

  • COPD-asthma market to reach $47bn in 2017

    These medicines include SkyePharma's Flutiform (fluticasone/formoterol) to treat asthma, Novartis' Arcapta Neohaler for patients with COPD, and GSK's own Seretide follow-up Relvar (formerly Relovair) for both asthma

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Interview: Georg Toufar, Mundipharma Interview: Georg Toufar, Mundipharma

    Treatments successfully brought to market in this way include asthma treatment Flutiform, created by Skye Pharma, and restless legs syndrome treatment Targin.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics